← FDA DRUG APPROVALS

FDA NDA · NDA021167

VIVELLE

Sponsor: NOVARTIS

APPLICATION
NDA021167
TYPE
NDA
ORIGINAL APPROVAL
2000-08-16
LATEST ACTION
2000-08-16
ROUTE
TRANSDERMAL
DOSAGE FORM
FILM, EXTENDED RELEASE
MARKETING STATUS
Prescription, Discontinued

Products

VIVELLEPrescription
ESTRADIOL 0.1MG/24HR · FILM, EXTENDED RELEASE · TRANSDERMAL
VIVELLEPrescription
ESTRADIOL 0.05MG/24HR · FILM, EXTENDED RELEASE · TRANSDERMAL
VIVELLEDiscontinued
ESTRADIOL 0.025MG/24HR · FILM, EXTENDED RELEASE · TRANSDERMAL
VIVELLEDiscontinued
ESTRADIOL 0.075MG/24HR · FILM, EXTENDED RELEASE · TRANSDERMAL
VIVELLEDiscontinued
ESTRADIOL 0.0375MG/24HR · FILM, EXTENDED RELEASE · TRANSDERMAL

Approval history

2000-08-16Type 9 - New Indication Submitted as Distinct NDA, Consolidated with Original NDA after Approval · Original · standardLabelAP
VIEW ON DRUGS@FDA ↗

Related on SPEQ

Pharma industryGMP disciplineFDA drug shortagesFDA enforcement & recalls

Source: FDA Drugs@FDA. SPEQ is not affiliated with the FDA; this is a reference view of public FDA data, not medical, legal, or regulatory advice.

Weekly Briefing

Get the Weekly GxP Briefing

Curated regulatory intelligence — enforcement, recalls, guidance, and quality signals — in one practitioner-grade email each week. Free.

Read a past issue →